• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Life sciences >The differentiating effect of glimepiride and glibenclamide on paraoxonase 1 and platelet-activating factor acetylohydrolase activity.
【24h】

The differentiating effect of glimepiride and glibenclamide on paraoxonase 1 and platelet-activating factor acetylohydrolase activity.

机译：格列美脲和格列本脲对过氧化物酶1和血小板活化因子乙酰水解酶活性的区分作用。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIMS: The present study was designed to examine the effect of sulphonylureas, glimepiride (GM) and glibenclamide (GB), on paraoxonase 1 (PON1) and platelet activating factor acetylohydrolase (PAF-AH) activity in normal and streptozotocin (STZ)-induced (50 mg/kg) diabetic rats. MAIN METHODS: In treated groups, glimepiride (0.1 mg/kg) or glibenclamide (2 mg/kg) was given orally for 4 weeks. A PON1 and PAF-AH activity were estimated by spectrophotometric method. KEY FINDINGS: Hyperglycemia was accompanied by a significant decrease in plasma PON1 activity toward paraoxon (P < 0.001) and phenyl acetate (P < 0.01) and increase in plasma PAF-AH activity (P < 0.01). In STZ-induced diabetic rats the administration of both GM and GB had no effect on plasma PON1 activity but reversed elevated plasma PAF-AH activity (GM: P < 0.05, GB: P < 0.01). In non-diabetic rats after either GM or GB administration the decreased PON1 activity in the plasma was observed (GM: P < 0.001, GB: P < 0.05), but plasma PAF-AH activity remained unchanged. Both GM and GB had no effect on total plasma antioxidant capacity in diabetic and control treated groups. Additionally, both drugs increased PON1 activity toward phenyl acetate in the liver, in diabetic rats (GM: P < 0.05, GB:ns) as well as in non-diabetic rats (GM: P < 0.001, GB: P < 0.001), and reduced lipid peroxidation in the liver. SIGNIFICANCE: These results demonstrate that in streptozotocin-induced diabetic rats as well as in normal rats glimepiride and glibenclamide have no beneficial effects on circulating PON1 and PAF-AH activities, but both drugs increase PON1 activity in the liver.
机译：目的：本研究旨在研究磺脲类，格列美脲（GM）和格列本脲（GB）对正常和链脲佐菌素（STZ）诱导的对氧磷酶1（PON1）和血小板活化因子乙酰水解酶（PAF-AH）活性的影响。 （50 mg / kg）糖尿病大鼠。主要方法：在治疗组中，口服格列美脲（0.1 mg / kg）或格列本脲（2 mg / kg）口服4周。通过分光光度法估计PON1和PAF-AH活性。主要发现：高血糖伴随着血浆PON1对对氧磷（P <0.001）和乙酸苯酯（P <0.01）的活性显着降低，以及血浆PAF-AH活性的升高（P <0.01）。在STZ诱导的糖尿病大鼠中，同时施用GM和GB对血浆PON1活性没有影响，但逆转了血浆PAF-AH活性的升高（GM：P <0.05，GB：P <0.01）。在服用GM或GB后的非糖尿病大鼠中，血浆中PON1活性降低（GM：P <0.001，GB：P <0.05），但血浆PAF-AH活性保持不变。在糖尿病和对照组中，GM和GB均对总血浆抗氧化能力没有影响。此外，在糖尿病大鼠（GM：P <0.05，GB：ns）和非糖尿病大鼠（GM：P <0.001，GB：P <0.001）中，这两种药物均会增加PON1对肝脏中乙酸苯酯的活性，并减少肝脏中的脂质过氧化。意义：这些结果表明，在链脲佐菌素诱导的糖尿病大鼠以及正常大鼠中，格列美脲和格列本脲对循环的PON1和PAF-AH活性没有有益作用，但两种药物均会增加肝脏中的PON1活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号